Atara Biotherapeutics (ATRA) Short Interest Ratio & Short Volume $10.42 +0.07 (+0.68%) (As of 11:33 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Atara Biotherapeutics Short Interest DataAtara Biotherapeutics (ATRA) has a short interest of 544,000 shares, representing 12.95% of the float (the number of shares available for trading by the public). This marks a 4.72% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.1, indicating that it would take 5.1 days of the average trading volume of 104,430 shares to cover all short positions.Current Short Interest544,000 sharesPrevious Short Interest519,500 sharesChange Vs. Previous Month+4.72%Dollar Volume Sold Short$6.62 millionShort Interest Ratio5.1 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares5,760,000 sharesFloat Size4,200,000 sharesShort Percent of Float12.95%Today's Trading Volume14,111 sharesAverage Trading Volume104,430 sharesToday's Volume Vs. Average14% Short Selling Atara Biotherapeutics? Sign up to receive the latest short interest report for Atara Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATRA Short Interest Over TimeATRA Days to Cover Over TimeATRA Percentage of Float Shorted Over Time Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Atara Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024544,000 shares $6.62 million +4.7%13.0%5.1 $12.18 11/15/2024519,500 shares $6.23 million -18.4%12.4%3.5 $12.00 10/31/2024636,300 shares $5.67 million -0.5%16.0%4.6 $8.91 10/15/2024639,200 shares $5.36 million +21.4%16.1%5.4 $8.38 9/30/2024526,400 shares $4.28 million +13.7%13.3%4.5 $8.13 9/15/2024463,000 shares $4.50 million +12.8%12.6%3.6 $9.72 Get the Latest News and Ratings for ATRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024410,500 shares $3.12 million +8.5%11.0%3.2 $7.60 8/15/2024378,500 shares $2.59 million +5.0%9.4%4.7 $6.83 7/31/2024360,500 shares $3.54 million -33.2%9.0%4.5 $9.83 7/15/2024540,000 shares $6.03 million -6.1%13.4%6.7 $11.16 6/30/2024575,300 shares $4.89 million +33.5%14.4%7.6 $8.50 6/15/2024431,000 shares $5.51 million -96.2%10.8%7.2 $12.78 5/31/202411,270,000 shares $6.32 million -3.0%N/A8.5 $0.56 5/15/202411,620,000 shares $7.44 million -2.2%N/A7.2 $0.64 4/30/202411,880,000 shares $8.20 million +3.8%N/A6.9 $0.69 4/15/202411,450,000 shares $7.77 million +2.0%N/A4.4 $0.68 3/31/202411,230,000 shares $7.79 million +1.8%N/A3.7 $0.69 3/15/202411,030,000 shares $6.85 million +8.8%N/A3.2 $0.62 2/29/202410,140,000 shares $7.89 million -6.7%N/A2.8 $0.78 2/15/202410,870,000 shares $8.39 million +44.4%N/A2.9 $0.77 1/31/20247,530,000 shares $4.70 million +2.7%N/A1.3 $0.62 1/15/20247,330,000 shares $5.27 million -20.2%N/A1.4 $0.72 12/31/20239,190,000 shares $4.71 million -9.3%N/A1.9 $0.51 12/15/202310,130,000 shares $6.08 million -8.8%N/A2.2 $0.60 11/30/202311,110,000 shares $7.33 million +36.2%N/A2.8 $0.66 11/15/20238,160,000 shares $3.10 million -34.7%N/A2.2 $0.38 10/31/202312,490,000 shares $16.11 million +1.8%N/A6.1 $1.29 10/15/202312,270,000 shares $18.90 million +6.3%N/A10.5 $1.54 9/30/202311,540,000 shares $17.08 million -1.1%N/A9.5 $1.48 9/15/202311,670,000 shares $17.86 million +1.2%N/A9.7 $1.53 8/31/202311,530,000 shares $16.83 million -5.4%N/A7.5 $1.46 8/15/202312,190,000 shares $22.43 million -5.9%N/A6.9 $1.84 7/31/202312,950,000 shares $28.62 million +2.6%N/A6.9 $2.21 7/15/202312,620,000 shares $23.09 million +7.9%N/A6.7 $1.83 6/30/202311,700,000 shares $18.84 million -11.4%N/A6 $1.61 6/15/202313,200,000 shares $28.25 million +4.6%N/A7 $2.14 5/31/202312,620,000 shares $19.31 million -11.0%N/A7.6 $1.53 5/15/202314,180,000 shares $31.20 million -20.3%N/A10 $2.20 4/30/202317,790,000 shares $48.21 million -7.4%N/A13.8 $2.71 4/15/202319,210,000 shares $51.67 million -3.8%N/A15.9 $2.69Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 3/31/202319,960,000 shares $57.88 million +19.5%N/A17.1 $2.90 3/15/202316,700,000 shares $51.44 million +18.7%N/A13.1 $3.08 2/28/202314,070,000 shares $56.98 million +0.4%N/A11.3 $4.05 2/15/202314,010,000 shares $63.47 million -1.3%N/A11.4 $4.53 1/31/202314,190,000 shares $71.94 million +4.1%N/A10.3 $5.07 1/15/202313,630,000 shares $53.02 million +4.8%N/A9.5 $3.89 12/30/202213,010,000 shares $42.67 million +5.0%N/A9.1 $3.28 12/15/202212,390,000 shares $42.87 million +1.2%N/A8.4 $3.46 11/30/202212,240,000 shares $55.45 million +1.6%N/A8.4 $4.53 11/15/202212,050,000 shares $60.37 million +1.1%N/A7.7 $5.01 10/31/202211,920,000 shares $55.55 million +0.2%N/A6.9 $4.66 10/15/202211,900,000 shares $44.39 million -3.4%N/A5.7 $3.73 9/30/202212,320,000 shares $46.57 million -0.2%N/A4.6 $3.78 9/15/202212,350,000 shares $58.05 million +10.2%N/A4.7 $4.70 8/31/202211,210,000 shares $44.95 million -0.6%N/A4.4 $4.01 8/15/202211,280,000 shares $60.24 million +7.0%N/A4.7 $5.34 7/31/202210,540,000 shares $31.94 million +31.1%N/A4.8 $3.03 7/15/20228,040,000 shares $30.95 million -24.9%N/A4.4 $3.85 6/30/202210,700,000 shares $83.35 million -5.1%N/A9.2 $7.79 6/15/202211,270,000 shares $62.55 million -3.9%N/A10.2 $5.55 5/31/202211,730,000 shares $61.00 million +6.4%N/A11 $5.20 5/15/202211,020,000 shares $0.00 -6.5%N/A9.9 $0.00 4/30/202211,790,000 shares $74.98 million +6.0%N/A11.7 $6.36 4/15/202211,120,000 shares $89.07 million +14.3%N/A11.2 $8.01 3/31/20229,730,000 shares $90.39 million +11.3%N/A9.6 $9.29 3/15/20228,740,000 shares $74.38 million +20.6%N/A9 $8.51 2/28/20227,250,000 shares $93.16 million +2.6%N/A7.7 $12.85 2/15/20227,070,000 shares $105.84 million +1.4%N/A8.6 $14.97 1/31/20226,970,000 shares $107.06 million +17.3%N/A8.1 $15.36 1/15/20225,940,000 shares $95.46 million -36.9%N/A7.1 $16.07 12/31/20219,420,000 shares $148.46 million +3.4%N/A11.3 $15.76 12/15/20219,110,000 shares $146.03 million +4.8%N/A10.7 $16.03 11/30/20218,690,000 shares $155.46 million -3.3%N/A11 $17.89 11/15/20218,990,000 shares $153.46 million -17.0%N/A10.7 $17.07 10/29/202110,830,000 shares $167.65 million -1.3%N/A13.4 $15.48 10/15/202110,970,000 shares $165.87 million -6.4%13.4%14.3 $15.12 9/30/202111,720,000 shares $209.79 million -6.1%14.4%16.4 $17.90 9/15/202112,480,000 shares $198.43 million +2.1%15.3%16.8 $15.90 8/31/202112,220,000 shares $183.06 million -4.4%15.0%16.2 $14.98 8/13/202112,780,000 shares $159.11 million -2.1%15.7%17.2 $12.45 7/30/202113,060,000 shares $166.52 million +8.0%16.1%16.7 $12.75 7/15/202112,090,000 shares $165.39 million +3.7%14.9%14.4 $13.68 6/30/202111,660,000 shares $181.31 million -7.7%14.4%12.4 $15.55 6/15/202112,630,000 shares $176.82 million -0.5%15.6%14.3 $14.00 5/28/202112,690,000 shares $172.08 million -0.7%15.7%13.9 $13.56 5/14/202112,780,000 shares $188.12 million +5.3%N/A13.5 $14.72 4/30/202112,140,000 shares $176.39 million -2.9%N/A13.2 $14.53 4/15/202112,500,000 shares $173.13 million -4.7%N/A0 $13.85 3/31/202113,120,000 shares $186.57 million +12.0%N/A15.2 $14.22 3/15/202111,710,000 shares $197.90 million +5.5%N/A13 $16.90Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 2/26/202111,100,000 shares $184.37 million -5.5%N/A11.6 $16.61 2/12/202111,740,000 shares $225.64 million -0.7%N/A12.4 $19.22 1/29/202111,820,000 shares $224.58 million +5.0%N/A11.7 $19.00 1/15/202111,260,000 shares $212.25 million -6.1%N/A11.6 $18.85 12/31/202011,990,000 shares $246.03 million -3.8%N/A13.3 $20.52 12/15/202012,460,000 shares $292.56 million +1.0%N/A14.2 $23.48 11/30/202012,340,000 shares $287.15 million -10.1%N/A13.5 $23.27 11/15/202013,730,000 shares $247.83 million -10.3%N/A16.4 $18.05 10/30/202015,310,000 shares $206.69 million -0.8%N/A19.7 $13.50 10/15/202015,440,000 shares $214.15 million +9.0%N/A19.1 $13.87 9/30/202014,170,000 shares $183.64 million +3.3%N/A17.4 $12.96 9/15/202013,720,000 shares $214.58 million -10.1%N/A12.9 $15.64 8/31/202015,260,000 shares $205.70 million +4.5%N/A14.3 $13.48 8/14/202014,610,000 shares $177.80 million +3.5%N/A11 $12.17 7/31/202014,110,000 shares $174.82 million -4.3%N/A8.9 $12.39 7/15/202014,740,000 shares $201.05 million +8.7%N/A9.1 $13.64 6/30/202013,560,000 shares $187.67 million +15.7%N/A7.9 $13.84 6/15/202011,720,000 shares $122.47 million -1.3%N/A7.7 $10.45 5/29/202011,870,000 shares $136.51 million -5.4%N/A8.4 $11.50 5/15/202012,550,000 shares $135.10 million +4.8%23.9%9.8 $10.77 4/30/202011,980,000 shares $99.31 million +17.1%22.8%14 $8.29 4/15/202010,230,000 shares $81.02 million +3.9%19.5%13 $7.92 3/31/20209,850,000 shares $87.27 million +1.1%18.9%14.4 $8.86 3/13/20209,745,100 shares $83.32 million -0.8%25.2%16.6 $8.55 2/28/20209,820,000 shares $77.48 million +5.4%25.3%15 $7.89 2/14/20209,320,000 shares $100.38 million -2.2%19.4%14.4 $10.77 1/31/20209,530,000 shares $106.55 million -5.4%19.9%14.8 $11.18 1/15/202010,070,000 shares $144.50 million +3.2%21.0%15.5 $14.35 12/31/20199,760,000 shares $132.93 million +2.0%20.3%14.4 $13.62 ATRA Short Interest - Frequently Asked Questions What is Atara Biotherapeutics' current short interest? Short interest is the volume of Atara Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 544,000 shares of ATRA short. 12.95% of Atara Biotherapeutics' shares are currently sold short. Learn More on Atara Biotherapeutics' current short interest. What is a good short interest ratio for Atara Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATRA shares currently have a short interest ratio of 5.0. Learn More on Atara Biotherapeutics's short interest ratio. What is a good short interest percentage for Atara Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.95% of Atara Biotherapeutics' floating shares are currently sold short. Is Atara Biotherapeutics' short interest increasing or decreasing? Atara Biotherapeutics saw a increase in short interest in November. As of November 30th, there was short interest totaling 544,000 shares, an increase of 4.7% from the previous total of 519,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Atara Biotherapeutics' float size? Atara Biotherapeutics currently has issued a total of 5,760,000 shares. Some of Atara Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atara Biotherapeutics currently has a public float of 4,200,000 shares. How does Atara Biotherapeutics' short interest compare to its competitors? 12.95% of Atara Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Atara Biotherapeutics: Fulcrum Therapeutics, Inc. (8.49%), Aurora Cannabis Inc. (8.05%), Fate Therapeutics, Inc. (9.97%), Lexeo Therapeutics, Inc. (9.24%), DiaMedica Therapeutics Inc. (0.35%), Zentalis Pharmaceuticals, Inc. (6.55%), Atai Life Sciences (8.71%), Tenaya Therapeutics, Inc. (21.42%), Aclaris Therapeutics, Inc. (3.47%), Acrivon Therapeutics, Inc. (5.07%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Atara Biotherapeutics stock? Short selling ATRA is an investing strategy that aims to generate trading profit from Atara Biotherapeutics as its price is falling. ATRA shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atara Biotherapeutics? A short squeeze for Atara Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRA, which in turn drives the price of the stock up even further. How often is Atara Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRA, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies FULC Short Interest Data ACB Short Interest Data FATE Short Interest Data LXEO Short Interest Data DMAC Short Interest Data ZNTL Short Interest Data ATAI Short Interest Data TNYA Short Interest Data ACRS Short Interest Data ACRV Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ATRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts